Identifying resistance to a single drug

Data from a number of studies such as ACTG 343 and Trilege indicated that viral rebound can occur when there are resistance mutations to only one drug in a combination. These findings have led to renewed interest in modifying failing combinations rather than switching to a completely new regimen. Resistance testing may have a role in determining which drug has become ineffective due to resistance during the early stages of viral rebound.

 

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.